The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Patient-reported quality of life (QoL) of advanced melanoma patients in a Phase 3 study of nivolumab (NIVO) with or without ipilimumab (IPI) versus IPI: CheckMate 067 4-year data.
 
Dirk Schadendorf
Honoraria - 4SC; Agenus; Amgen; Array BioPharma; AstraZeneca; Bristol-Myers Squibb; Grunenthal; Immunocore; Incyte; LEO Pharma; Merck Serono; Merck Sharp & Dohme; Mologen; Novartis; Pfizer; Philogen; Pierre Fabre; Regeneron; Roche/Genentech; Sysmex
Consulting or Advisory Role - 4SC; Amgen; Bristol-Myers Squibb; Immunocore; Incyte; Merck Serono; Merck Sharp & Dohme; Mologen; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Incyte; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck; Merck Serono; Novartis; Roche/Genentech
 
James M.G. Larkin
Honoraria - Achilles Therapeutics; AstraZeneca; Boston Biomedical; Bristol-Myers Squibb; Eisai; EUSA Pharma; GlaxoSmithKline; Imugene; Incyte; iOncologi; Ipsen; Kyocera; Merck Serono; MSD; Nektar; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sectra; Vitaccess
Consulting or Advisory Role - Achilles Therapeutics; AstraZeneca; Boston Biomedical; Bristol-Myers Squibb; Eisai; EUSA Pharma; GlaxoSmithKline; Imugene; Incyte; iOncologi; Ipsen; Kyocera; Merck Serono; MSD; Nektar; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sectra; Vitaccess
Research Funding - Achilles Therapeutics (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Covance (Inst); Immunocore (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis; Pfizer; Roche/Genentech
 
Jedd D. Wolchok
Stock and Other Ownership Interests - Adaptive Biotechnologies; Ascentage Pharma; Beigene; Elucida Oncology; Imvaq Therapeutics; Kleo Pharmaceuticals; Linnaeus Therapeutics; Potenza Therapeutics; Serametrix; Tizona Therapeutics, Inc.; Trieza Therapeutics
Honoraria - American Association for Cancer Research; Esanex; Institut Jules Bordet
Consulting or Advisory Role - Adaptive Biotechnologies; Advaxis; Amgen; Apricity Therapeutics; Array BioPharma; Ascentage Pharma; Astellas Pharma; Bayer; Beigene; Bristol-Myers Squibb; Celgene; Chugai Pharma; F-Star Biotechnology; Genentech; Kleo Pharmaceuticals; Lilly; MedImmune; Merck; Neon Therapeutics; Ono Pharmaceutical; Polaris; Polynoma; Potenza Therapeutics; PsiOxus Therapeutics; PsiOxus Therapeutics; PureTech; Sellas Life Sciences; Serametrix; Surface Oncology; Syndax; Tizona Therapeutics, Inc.; Trieza Therapeutics
Research Funding - Bristol-Myers Squibb (Inst); F-Star Therapeutics; Genentech/Roche (Inst); Incyte (Inst); Leap Therapeutics (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst)
Patents, Royalties, Other Intellectual Property - ALPHAVIRUS REPLICON PARTICLES EXPRESSING TRP2; Engineered Vaccinia Viruses for Cancer Immunotherapy; I am a co-inventor and receive royalties for a blood test for monitoring myeloid derived suppressor cells.; I am a co-inventor on a patent for Anti-CD40 agonist mAb fused to Monophosphoryl Lipid A (MPL) for cancer therapy; I am a co-inventor on a patent for CAR+ T cells targeting differentiation antigens as means to treat cancer; I am a co-inventor on a patent for use of oncolytic Newcastle Disease virus.; I am a co-inventor on an issued patent for DNA vaccines for treatment of cancer in companion animals.; I am co-inventor and receive royalties for a patent for immune modulating antibodies.
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Bristol-Myers Squibb; Celgene; Chugai Pharma; Janssen; MedImmune; Novartis; Ono Pharmaceutical; Potenza Therapeutics; Roche; Tizona Therapeutics, Inc.
 
Vanna Chiarion-Sileni
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Serono; MSD Oncology; Novartis; Pierre Fabre; Roche; Roche
Speakers' Bureau - Bristol-Myers Squibb; Novartis
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Fiona Taylor
Employment - Adelphi
 
Rachael Lawrance
Employment - Adelphi
Stock and Other Ownership Interests - AstraZeneca
 
Alejandro Moreno-Koehler
Employment - Adelphi
 
Jennifer Lord-Bessen
Employment - Bristol-Myers Squibb; Bristol-Myers Squibb
 
Jasmine I. Rizzo
Employment - Bristol-Myers Squibb
 
Andriy Moshyk
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
SRIVIDYA KOTAPATI
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
F. Stephen Hodi
Employment - Dana-Farber Cancer Institute
Stock and Other Ownership Interests - Apricity Health
Consulting or Advisory Role - Aduro Biotech; Amgen; Bayer; Bristol-Myers Squibb; Celldex; EMD Serono; Genentech/Roche; Incyte; Incyte; Incyte; Merck Sharp & Dohme; Novartis; Pfizer; Sanofi; Verastem
Research Funding - bristol-myers squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); novartis (Inst)
Patents, Royalties, Other Intellectual Property - Angiopoietin-2 Biomarkers Predictive of Anti-immune checkpoint response (Inst); Compositions and Methods for Identification, Assessment, Prevention, and Treatment of Melanoma using PD-L1 Isoforms; Methods of Using Pembrolizumab and Trebananib (Inst); patent pending as per institutional policy; patent pending royalties received on MICA related disorders application to institution per institutional IP policy
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis
Other Relationship - Bristol-Myers Squibb; Genentech/Roche